Neutralization of IL-6 (BE-8) and Its Receptor CD126 (PM-1) Prevented Differentiation by Inducing Apoptosis of Plasmablasts
| . | RP5 . | RP8 . | RP9 . | |||
|---|---|---|---|---|---|---|
| CD138+ . | Apo2.7+ . | CD138+ . | Apo2.7+ . | CD138+ . | Apo2.7+ . | |
| Treatment | ||||||
| Nil | 25% | 13% | 14% | 8% | 6% | 4% |
| Anti–IL-6 MoAb | 9% | 42% | ND | ND | ND | ND |
| Anti–IL-6 + anti-CD126 MoAbs | ND | ND | 0.5% | 25% | 0.2% | 10% |
| Anti-FGF basic Ab | 24% | 15% | ND | ND | 7.5% | ND |
| FGF basic | 26% | ND | ND | ND | 6.8% | ND |
| . | RP5 . | RP8 . | RP9 . | |||
|---|---|---|---|---|---|---|
| CD138+ . | Apo2.7+ . | CD138+ . | Apo2.7+ . | CD138+ . | Apo2.7+ . | |
| Treatment | ||||||
| Nil | 25% | 13% | 14% | 8% | 6% | 4% |
| Anti–IL-6 MoAb | 9% | 42% | ND | ND | ND | ND |
| Anti–IL-6 + anti-CD126 MoAbs | ND | ND | 0.5% | 25% | 0.2% | 10% |
| Anti-FGF basic Ab | 24% | 15% | ND | ND | 7.5% | ND |
| FGF basic | 26% | ND | ND | ND | 6.8% | ND |
Fluorescence analysis at day 3 of CD138 and APO2.7 expression in untreated or treated cells, as indicated (anti–IL-6, B-E8: 50 μg/mL; anti-CD126, PM-1: 10 μg/mL; anti-FGF: 50 μg/mL; rFGF basic: 10 ng/mL). The percentages of positive cells for CD138 or APO2.7 were determined in the total population.